Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thymus Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Thymus Cancer - Pipeline Review, H1 2015', provides an overview of the Thymus Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Thymus Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thymus Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thymus Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thymus Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Thymus Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Thymus Cancer - Overview 7 Pipeline Products for Thymus Cancer - Comparative Analysis 8 Thymus Cancer - Therapeutics under Development by Companies 9 Thymus Cancer - Therapeutics under Investigation by Universities/Institutes 10 Thymus Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Thymus Cancer - Products under Development by Companies 12 Thymus Cancer - Products under Investigation by Universities/Institutes 13 Thymus Cancer - Companies Involved in Therapeutics Development 14 Merck & Co., Inc. 14 Novartis AG 15 Onxeo SA 16 Sumitomo Dainippon Pharma Co., Ltd. 17 Thymus Cancer - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 amrubicin hydrochloride - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 belinostat - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 buparlisib hydrochloride - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cell Therapy 1 for Oncology - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 milciclib - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 MK-2206 + selumetinib sulfate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 pembrolizumab - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Thymus Cancer - Recent Pipeline Updates 48 Thymus Cancer - Product Development Milestones 64 Featured News & Press Releases 64 Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 64 May 14, 2014: Phase II data of Nerviano Medical Science's kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 64 Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas 65 May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012 65 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Thymus Cancer, H1 2015 7 Number of Products under Development for Thymus Cancer - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Thymus Cancer - Pipeline by Merck & Co., Inc., H1 2015 14 Thymus Cancer - Pipeline by Novartis AG, H1 2015 15 Thymus Cancer - Pipeline by Onxeo SA, H1 2015 16 Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 17 Assessment by Monotherapy Products, H1 2015 18 Assessment by Combination Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Thymus Cancer Therapeutics - Recent Pipeline Updates, H1 2015 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.